Pre-Dose THC Positivity Had Different Eligibility Rules in the Cannabis Metabolomics Study
The metabolomics experiment permitted residual pre-dose THC in chronic users but required occasional users to pass the drug screen before dosing. A positive screen did not carry one identical protocol meaning across the study groups.
The study specified different admission conditions
Occasional users who tested positive on the test-day drug screen were sent home to return later. Chronic users could proceed with positive THC results if their screens were negative for other drugs and alcohol. The paper reports that chronic users were consistently THC-positive before experimental dosing. These rules reflect the selected use-history groups and should remain explicit when interpreting the baseline.
Residual detection was not the experimental challenge
Pre-dose THC in chronic users was distinct from the vaporized cannabis administered during the controlled session. The study collected baseline serum and compared cannabis and placebo conditions. A residual positive therefore did not mean the participant had already received the study dose or establish a measured functional deficit by itself.
Eligibility affects the comparison
The two groups did not enter with identical chemical starting conditions. That does not automatically invalidate the experiment, but it limits an account portraying both groups as analytically THC-free before treatment. The study also did not validate its admission rule as a workplace, clinical or driving standard. Its protocol illustrates why the specimen, timing, use history and stated screening criteria must be distinguished before a positive result is interpreted as evidence of new dosing or current impairment.
Related analysis: the study’s broader findings and limitations.
